Artículo

Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?

Mazzolini Rizzo, Guillermo DanielIcon ; Iracheta, Alexis; Malvicini, MarianaIcon ; Bayo Fina, Juan MiguelIcon
Fecha de publicación: 09/2020
Editorial: John Wiley & Sons
Revista: Clinical Liver Disease
e-ISSN: 2046-2484
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:

Resumen

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide, and its mortality is increasing steadily.1 HCC incidence has grown in the last twenty years driven at least in part by the epidemic of nonalcoholic fatty liver disease (NAFLD).2 Unfortunately, overall survival rate for patients with HCC at 5 years is near 18%, which reflects how complex and resistant to systemic therapies this devastating disease is.2 Although new systemic drugs have been approved for advanced HCC in the first and second line, prolonging overall survival beyond a year is still difficult.1
Palabras clave: HEPATOCELLULAR CARCINOMA , IMMUNOTHERAPY , CLINICAL TRIALS , LATIN AMERICAN EXPERIENCE
 
Archivos asociados
Tamaño: 719.3Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/185333
URL: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/cld.919
DOI: https://doi.org/10.1002/cld.919
Colecciones
Articulos(IIMT)
Articulos de INSTITUTO DE INVESTIGACIONES EN MEDICINA TRASLACIONAL
Citación
Mazzolini Rizzo, Guillermo Daniel; Iracheta, Alexis; Malvicini, Mariana; Bayo Fina, Juan Miguel; Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?; John Wiley & Sons; Clinical Liver Disease; 16; 3; 9-2020; 96-100
Compartir
Altmétricas